[Endocrine treatment of meningiomas: a review].
Meningiomas are benign tumors of central nervous system. They have high rates of relapse and sometimes are not amenable to total removal mainly when involve vital structures. Clinical, epidemiological, biochemical and "in vitro" experiment show evidence that meningioma growth is influenced by steroid hormonal medium. Several clinical trials have explored these meningioma characteristics with the use of substances interfering with steroid actions: RU486 (antiprogestinic and antiglucocorticoid), medroxiprogesterone acetate (antiprogestinic), gestrinone (antiestrogenic e antiprogestinic), tamoxifen (antiestrogenic) and buserelin (LHRH superagonist), beyond of octreotide (somatostatin analog) and bromocriptine (dopaminergic agonist). Other substances have potential for the meningiomas treatment: aminogluthetimide, suramin and trapidil. In this review, we analyzed the literature about these aspects.
D000818:Animals; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008579:Meningioma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D015735:Mifepristone / Q000627:therapeutic use*; D011987:Receptors, Steroid; D012737:Sex Factors
D006727:Hormone Antagonists; D011987:Receptors, Steroid; D015735:Mifepristone
Tratamento endócrino dos meningiomas: uma revisão.